Search clinical trials for: AZD8233

Total 83 results

AstraZeneca

Terminated

Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment (CHIVE)

Breast Neoplasm

Korea, Republic of, Germany, Taiwan
AstraZeneca
Parexel

Completed

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

Healthy Volunteers

United States
AstraZeneca
Parexel

Completed

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

Healthy Volunteers

United States
AstraZeneca
Eli Lilly and Company

Completed

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Healthy

United States
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

ER-positive, HER2-negative Breast Cancer

United Kingdom
AstraZeneca

Completed

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Advanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation

United States, United Kingdom
AstraZeneca
ImaginAb, Inc.

Terminated

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

Carcinoma, Non-Small-Cell Lung | Urinary Bladder Neoplasms | Colorectal Cancer

United States, Canada
Sichuan University

Recruiting

CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma

Multiple Myeloma

China
Luca Ronfani
University of Trieste

Completed

Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models

Urea Cycle Disorders, Inborn | Other Metabolic Diseases

Italy
AstraZeneca

Completed

Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.

Neoplasms | Breast Cancer | Metastatic Cancer

Japan
AstraZeneca

Completed

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Healthy Participants

United States
AstraZeneca

Completed

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) (THYME)

Neoplasms | Breast Cancer | Breast Neoplasms

Brazil, Bulgaria, Czech Republic, Peru, Spain, United Kingdom, Sweden, Hungary, Belgium, Canada, Italy, France, Panama, Switzerland
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
AstraZeneca

Active, not recruiting

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

ER-Positive HER2-Negative Breast Cancer

Austria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
AstraZeneca

Terminated

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

Metastatic, Gastric or Gastro-oesophageal Junction, Cancer

Korea, Republic of, Spain, Taiwan, Germany, Japan
AstraZeneca

Active, not recruiting

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (SERENA-2)

Advanced ER-Positive HER2-Negative Breast Cancer

United States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
AstraZeneca
Eli Lilly and Company

Completed

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin

Healthy

United States
AstraZeneca

Completed

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate (AZD3293DDI)

Healthy Volunteers | Pharmacologic Action

United States
AstraZeneca
Parexel

Completed

AZD3293 Thorough QT Study in Healthy Male Volunteers (AZD3293TQT)

Alzheimer's Disease

United States
AstraZeneca

Terminated

A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease | COPD

Poland, Sweden
AstraZeneca

Terminated

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer (MINT)

Neoplasms | Breast Cancer | Breast Neoplasms

Brazil, Czech Republic, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, South Africa, United Kingdom, Philippines, Ukraine, Finland, Canada, Taiwan, India, Thailand, United States, Japan
University College, London
AstraZeneca; Cancer Research UK; National Institute for Health Research, United...

Completed

Phase I/II Trial of Antagonism of HER in GI Cancer (PANTHER)

Metastatic Colorectal Cancer | Recurrent Colorectal Cancer

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Healthy Subjects

United Kingdom
UNICANCER
AstraZeneca; Intergroupe Francophone de Cancerologie Thoracique; Fondation ARC

Completed

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (SAFIR02_Lung)

Non-small Cell Lung Cancer Metastatic

France
AstraZeneca
Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2)

Breast Cancer, Early Breast Cancer

United States, Spain, Italy, Korea, Republic of, Belgium, Canada, Poland, Portugal, United Kingdom, France, China, Germany, Japan, Mexico, Thailand, Hungary, Australia, Austria, Brazil, Colombia, Taiwan, Malaysia, Philippines, Romania, ... and more
AstraZeneca

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

Breast Cancer, Early Breast Cancer

United States, Canada, United Kingdom, China, Argentina, Australia, Hungary, Netherlands, Korea, Republic of, France, Germany, Italy, Belgium, Bulgaria, India, Mexico, Spain, Vietnam, Colombia, Japan, Peru, Brazil, Malaysia, Taiwan, Tha... and more
AstraZeneca

Completed

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

Diabetic Neuropathy, Painful; Diabetic Neuropathies

United States
AstraZeneca
Eli Lilly and Company

Completed

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy

United States
AstraZeneca

Completed

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

Healthy Volunteers

United States
Duke University
National Institutes of Health (NIH)

Completed

Treatment of Mood and Marriage Study (TOMMS)

Major Depressive Disorder | Partner Relational Disorder (V61.10)

United States
UNICANCER
AstraZeneca; Fondation ARC

Active, not recruiting

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (SAFIR02_Breast)

Metastatic Breast Cancer

France

Search clinical trials for: AZD8233

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations